1
Curriculum Vitae
Jacques Henri Edmond Grosset, MD
DEMOGRAPHIC INFORMATION
Current Appointments:
- Emeritus Professor of Bactériologie-Virologie-Hygiène, Faculty of Medicine Pitié Salpêtrière, University Pierre and Mary Curie, Paris VI
- Visiting Professor, Center for Tuberculosis Research, Johns Hopkins School of Medicine,
Personal Data
Date of birth: September 16, 1929
Citizenship: French
Marital Status: Married, 1957. 4 children born: 1959, 1960, 1962, 1966
Home address: Business Address:
500 W. University Parkway, Apt14C Center for Tuberculosis Research
Baltimore, MD 21210-3299 Dept. of Medicine, Div. of Infectious Diseases
Tel: 410-889-6247. Johns Hopkins School of Medicine
424 N. Bond Street
Baltimore, MD 21231
Tel: 410-955-3507
Fax: 410-614-8173
E-mail:
Education and Training:
Baccalaureate. 1947 Lille University, France
Medical studies. 1947-1954 Lille University , Faculty of Medicine
M.D. 1956 Paris University
Internal Med. Residency 1955-1959 Foundation Sanatorium Etudiants de France
Medical Director: Dr René Cohen
Pasteur Institute Fellow 1955-1956
Medical Licensure 1956 Paris
Diplomate Bact. & Vir. 1956 Paris University
Diplomate Immunology 1956 Paris University
Certified Prof. of Bact. Vir. Parasit. 1965 National Board of Microbiology
Professional experience:
Assistant, Department of Tuberculosis (Head Dr. Georges Canetti)
Pasteur Institute, Paris, France 1956 - 1963
Chief of Laboratory, Head of the Mycobacteria Department
Pasteur Institute, Algiers, Algeria 1963 – 1970
Professor of Bacteriology and Virology,
Faculty of Medicine, Algiers, Algeria 1966 - 1970
Professor of Bacteriology, Virology, and Hygiene
Faculty of Medicine Pitié-Salpêtrière, Paris, France 1970 – 1999
Emeritus Professor of Bacteriology, Virology, and Hygiene, 1999- present Faculty of Medicine Pitié Salpêtrière
Visiting Professor, Center for Tuberculosis Research
Johns Hopkins School of Medicine 01/02 – present
Affiliations
Foundation Sanatorium Etudiants de France, 1956-1959
Post-cure, Rue du Conventionel Chiappe, Paris
Physician responsible for the tuberculosis laboratory, 1963-1970 Pasteur Institute, Algiers
Physician responsible for BCG vaccination, 1966-1970 Pasteur Institute, Algiers
Deputy Director Central Laboratory for Bacteriology and Virology 1970-1977 Pitie-Salpetriere University Hospital, Paris
Director Central Laboratory for Bacteriology and Virology 1977-1996 Pitie-Salpetriere University Hospital, Paris
Consulting Professor in the pneumology department 1996-1999 Pitié Salpêtrière Hospital, Paris
Physician coordinator of tuberculosis control among homeless,
Social Emergency Unit (Samu Social), Paris, France 1999 - 2001
RESEARCH ACTIVITIES
Publications:
Journal articles (peer-reviewed)
Year 2004
Nuermberger EL, T. Yoshimatsu, S. Tyagi, WR Bishai, and JH Grosset. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect. Immun. In press
Nuermberger EL, T. Yoshimatsu, S. Tyagi, RJ O’Brien, AN Vernon, RE Chaisson, WR Bishai, and JH Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. In press
Year 2003
Emmanuelli X, J Grosset. 2003. Tuberculose et pauvreté. Rev Mal Respir 20: 1-3.
Ginsburg AS, JH Grosset, and WR Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. The Lancet Infectious Diseases 3: 432-442.
Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47: 833-836.
Lamichane G, M. Zignol, NJ Blades, DE Geiman, A Dougherty, J Grosset, KW Broman, and WR Bishai. 2003. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. PNAS 100: 7213-7218.
Lounis N., C. Maslo, C. Truffot-Pernot, J. Grosset, RJ Boelaert. 2003. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis. 7: 575-12.
Quy HTW, NTN.Lan, MW. Borgdorff, J. Grosset, PD Linh, LB. Tung, D. van Soolingen, M. Raviglione, NV Cô, J. Broekmans.2003. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis. 7: 631-636.
Robert J, D Trystram, C Truffot, J Grosset. 2003. La multiresistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992. Med Mal Infect. 33(S3): 183s-187s.
Year 2002
Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of the combination rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother.46:3193-3196.
Grosset, J., L. Zunic, and C. Morcrette. 2002. [World epidemiology of tuberculosis and resistance against anti-tuberculosis drugs]. Ann Med Interne (Paris). 153:107-12.
Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 46:1875-1879.
Year 2001
Astagneau, P., N. Desplaces, V. Vincent, V. Chicheportiche, A. Botherel, S. Maugat, K. Lebascle, P. Leonard, J. Desenclos, J. Grosset, J. Ziza, and G. Brucker. 2001. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet. 358:747-51
Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 45:3109-12
Boelaert, J. R., R. Appelberg, M. S. Gomes, E. Blasi, R. Mazzolla, J. Grosset, N. Lounis, K. Soteriadou, M. Thiakaki, D. Taramelli, and C. Tognazioli. 2001. Experimental results on chloroquine and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr. 26:300-1.
Grosset, J. H. 2001. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis. 69:S14-8.
Grosset, J. H., and S. T. Cole. 2001. Genomics and the chemotherapy of leprosy. Lepr Rev. 72:429-40.
Honore, N., P. W. Roche, J. H. Grosset, and S. T. Cole. 2001. A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev. 72:441-8.
Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 45:3482-6.
Lounis, N., C. Truffot-Pernot, A. Bentoucha, J. Robert, B. Ji, and J. Grosset. 2001. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 45:3229-30.
Lounis, N., C. Truffot-Pernot, J. Grosset, V. R. Gordeuk, and J. R. Boelaert. 2001. Iron and Mycobacterium tuberculosis infection. J Clin Virol. 20:123-6.
Year 2000
Cambau, E., C. Truffot-Pernot, F. Boulahbal, C. Wichlacz, J. Grosset, and V. Jarlier. 2000. Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis. 19:938-42.
Consigny, S., A. Bentoucha, P. Bonnafous, J. Grosset, and B. Ji. 2000. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 44:2919-21.
Daniel, N., N. Lounis, B. Ji, R. J. O'Brien, A. Vernon, L. J. Geiter, M. Szpytma, C. Truffot-Pernot, G. Hejblum, and J. Grosset. 2000. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med. 161:1572-7.
Dega, H., O. Chosidow, S. Barete, B. Carbonnelle, J. Grosset, and V. Jarlier. 2000. [Mycobacterium ulcerans infection]. Ann Med Interne (Paris). 151:339-44.
Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 44:2367-72.
Grosset, J. 2000. The new challenges for chemotherapy research. Lepr Rev. 71:S100-4.
Ji, B., and J. Grosset. 2000. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev. 71:S81-7.
Nguyen, L. N., J. L. Cartel, and J. H. Grosset. 2000. Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev. 71:S33-5; discussion S35-6.
Robert, J., D. Trystram, C. Truffot-Pernot, E. Cambau, V. Jarlier, and J. Grosset. 2000. Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective. Int J Tuberc Lung Dis. 4:504-12.
Robert, J., D. Trystram, C. Truffot-Pernot, B. Carbonnelle, and J. Grosset. 2000. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis. 4:665-72.
Year 1999
Flament-Saillour, M., J. Robert, V. Jarlier, and J. Grosset. 1999. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 160:587-93.
Grosset J. 1999. A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France. Int J Tuberc Lung Dis. 3:711-4.
Grosset, J. 1999. [Which strategies for eradication of tuberculosis?]. Bull Acad Natl Med. 183:25-37; discussion 37-40.
Grosset, J. 1999. [Leprosy and tuberculosis: opposite results?]. Med Trop (Mars). 59:25-30.
71. 72.
Grosset J. Systematic drug susceptibility testing : a necessary component of the "DOT Plus" strategy? Int. Tuberc. Lung Dis. 1999; 3 : 549-550.
Lounis, N., C. Truffot-Pernot, R. G. Ridley, G. Alber, and J. H. Grosset. 1999. Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice. Clin Microbiol Infect. 5:331-338.
Rinder, H., K. Feldmann, E. Tortoli, J. Grosset, M. Casal, E. Richter, M. Rifai, V. Jarlier, M. Vaquero, S. Rusch-Gerdes, E. Cambau, J. Gutierrez, and T. Loscher. 1999. Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples. Mol Diagn. 4:145-52.
Robert, J., F. Boulahbal, D. Trystram, C. Truffot-Pernot, A. C. de Benoist, V. Vincent, V. Jarlier, and J. Ji, B., and J. H. Grosset. 1999. Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis. 67:S45-55
Year 1998
Carbonne, A., N. Lemaitre, M. Bochet, C. Truffot-Pernot, C. Katlama, J. Grosset, F. Bricaire, and V. Jarlier. 1998. Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility. Infect Control Hosp Epidemiol. 19:784-6.
Craft, J. C., G. F. Notario, J. H. Grosset, and L. B. Heifets. 1998. Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. Clin Infect Dis. 27:807-12.
Grosset, J. H., and S. Franzblau. 1998. Report of workshop on chemotherapy. Int J Lepr Other Mycobact Dis. 66:595-6.
Grosset, J. 1998. [What's new for tuberculosis in 1998?]. Rev Med Interne. 19:613-6.
Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med. 157:1436-40.
Grosset, J., and C. Truffot-Pernot. 1998. [Mycobacterium xenopi, a newcomer?]. Rev Prat. 48:701-3.
Ji, B., S. Sow, E. Perani, C. Lienhardt, V. Diderot, and J. Grosset. 1998. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 42:1115-20.
Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 42:2066-9.
Jouveshomme, S., E. Cambau, D. Trystram, M. Szpytma, W. Sougakoff, J. P. Derenne, and J. Grosset. 1998. Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. Am J Respir Crit Care Med. 158:1096-101.
Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, E. Cambau, J. P. Derenne, F. Bricaire, J. Grosset, and V. Jarlier. 1998. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc Lung Dis. 2:390-6.
Schwoebel, V., B. Decludt, A. C. de Benoist, S. Haeghebaert, G. Torrea, V. Vincent, and J. Grosset. 1998. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. British.Medical.J. 317:630-1.
Year 1997
Dautzenberg, B., C. Truffot-Pernot, J. Hazebroucq, S. Legris, C. Guerin, C. Begelman, G. Guermonprez, M. H. Fievet, C. Chastang, and J. Grosset. 1997. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection. 25:16-21.
Gimenez, F., V. Leblond, J. Nguyen, P. Serrand, J. L. Binet, J. Grosset, and A. Thuillier. 1997. Variations of teicoplanin concentrations in neutropenic patients. J Clin Pharm Ther. 22:187-90.
Grosset, J., and B. Ji. 1997. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs. 54:23-7; discussion 28-9.
Grosset, J. 1997. Whither short-course chemotherapy for leprosy? Indian J Lepr. 69:119-20.
Iborra, C., E. Cambau, C. Lecomte, J. Grosset, F. Bricaire, and E. Caumes. 1997. [Cutaneous tuberculosis. A study of 4 cases]. Ann Dermatol Venereol. 124:139-43.
Ji, B., P. Jamet, S. Sow, E. G. Perani, I. Traore, and J. H. Grosset. 1997. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother. 41:1953-6
Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother. 41:607-10.
Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Antimicrob Agents Chemother. 41:1168-9.
Mane, I., J. L. Cartel, and J. H. Grosset. 1997. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis. 65:224-9.
May, T., F. Brel, C. Beuscart, V. Vincent, C. Perronne, T. Doco-Lecompte, T. Saint-Marc, B. Dautzenberg, and J. Grosset. 1997. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis. 25:621-9.
Wyplosz, B., C. Truffot-Pernot, J. Robert, V. Jarlier, and J. Grosset. 1997. [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections]. Rev Mal Respir. 14:S33-48.
Year 1996
Doucet-Populaire, F., V. Lalande, E. Carpentier, A. Bourgoin, M. Dailloux, C. Bollet, A. Vachee, D. Moinard, J. Texier-Maugein, B. Carbonnelle, and J. Grosset. 1996. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tuber Lung Dis. 77:358-62.
Grosset, J. 1996. [Bacteriological diagnosis of tuberculosis]. Rev Prat. 46:1337-43.
Grosset J.. 1996. L'approche expérimentale de la chimiothérapie de la tuberculose.
Méd. Mal. Infect.; 26 : 922-925.
Grosset J. Résurgence de maladies anciennes : la tuberculose.
Rev. Epid. Santé Publique 1996 ; 44 (suppl. 2) : S11.
Grosset, J. 1996. Current problems with tuberculosis treatment. Res Microbiol. 147:10-6.
Ji, B., P. Jamet, E. G. Perani, S. Sow, C. Lienhardt, C. Petinon, and J. H. Grosset. 1996. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother. 40:2137-41.